Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir versus ribavirin for Lassa fever
PACTR202010817169062Phase 2Completed
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
- Start
- May 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Lassa fever comparing Favipiravir with Ribavirin Irrua regimen (2 arms). Primary endpoints: Pharmacokinetics, Tolerability and 1 more. Started May 2021; status: completed.
02
Drugs
favipiravirribavirin
03
Conditions
Lassa fever
Beyond the preview
Go deeper on PACTR202010817169062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202010817169062.